1,721,072 research outputs found
La giurisprudenza di Strasburgo 2008-2010: il diritto di proprietà (art. 1 Prot. 1 CEDU)
No full textRecenti sviluppi in tema di riserva di legge in materia penale e retroattività della lex mitior: a proposito della sentenza della Corte costituzionale sulle ceneri di pirite
No full text
Hemostasis Components as Therapeutic Targets in Autoimmune Demyelination
No full textSeveral studies in both multiple sclerosis (MS) and experimental autoimmune encephalitis (EAE) have shed light on the vascular mechanisms contributing to MS pathogenesis. The dysregulation of the hemostatic pathways revealed to play a pivotal role. Here, we review the numerous findings providing evidence on the involvement of hemostasis components in MS pathogenesis to highlight why they might be considered potential therapeutic targets in the disease. A literature search for articles from January 1950 to September 2021 was conducted in PubMed and Scopus. A consistent body of evidence supports the pro-inflammatory activity of activated platelets in MS pathogenesis and the beneficial effect of aspirin administration on the EAE clinical course. Further, neuropathological findings in subjects with MS and experimental studies in EAE have revealed dysregulation of coagulation/fibrinolysis system in autoimmune demyelination. Fibrin deposition in the central nervous system and its interaction with the CD11b receptor on microglia cells seems to drive neuroinflammation and autoimmune demyelination. However, at present, few and controversial clinical data are available on the implementation of drugs targeting fibrin deposition in MS therapy. In conclusion, targeting platelet activation and receptors for fibrin(ogen) deserve further research to hopefully purpose new drugs in the pharmacologic paraphernalia of MS neurologists
Heidenhain variant of Creutzefeldt-Jackob disease in a patient carrying the V210I mutation with asymmetric MRI abnormalities
No full text
Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab
No full textAssociation between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic
No full textBackground: Stress is a potential trigger for clinical and radiological activity in Multiple Sclerosis (MS). COVID-19 pandemic has been a relevant source of mental distress in people with MS (pwMS) and deeply impacted on disease management. Objective: To investigate the association between stress, anxiety, depression, and risk of relapse during the COVID-19 pandemic. Methods: From an electronic database used for clinical practice, we extracted data of relapsing–remitting (RR) or relapsing-progressive (RP) MS patients and calculated the annualized relapse rate (ARR) during 2019 and 2020. From 01/12/2020 to 30/12/2020, enrolled patients were invited to fill in a Google Forms survey to investigate depression, anxiety, stress, and Post-Traumatic Stress Disorder (PTSD). Results: We selected 216 patients with RR or RP-MS to calculate ARR: compared to 2019, in 2020 there was a significant increase in ARR (p = 0.0142). Over 216 selected pwMS, 154 completed the survey. Matching the survey responses and incidence of relapses in 2020, there was a significant association between relapses and stress (p = 0.030) and relapses and depression (p = 0.011), but not between relapses and anxiety (p = 0.130) or PTSD (p = 0.279). Conclusions: Our results support the hypothesis that pandemic-related stress is associated to clinical exacerbations, both as a possible consequence of the COVID-19 impact on MS care
- …
